ReviewMolecular biology reports2026
MicroRNAs and polymorphisms influencing MICA immune modulation.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
MicroRNAs (miRNAs) are small non-coding RNAs that play a central role in post-transcriptional gene regulation. They act mainly by interacting with sequences located in the 3' untranslated regions (3'UTRs) of messenger RNAs (mRNAs), thereby influencing mRNA stability and translation. Through these mechanisms, miRNAs contribute to the fine-tuning of multiple biological pathways, including immune activation, inflammatory signaling, and cellular stress responses. Among the genes involved in immune surveillance, the major histocompatibility complex class I polypeptide-related sequence A (MICA) has emerged as an important target for post-transcriptional regulation due to its role as a ligand for the activating receptor NKG2D (natural killer cell group 2-D), which is expressed in natural killer (NK) cells and cytotoxic T lymphocytes. MICA is highly polymorphic, and several allelic variants differ in sequence composition, structural organization, and expression patterns, potentially influencing miRNA-mRNA interactions. Growing evidence suggests that miRNA-mediated regulation of MICA contributes to immune modulation in cancer, viral infections, and autoimmune disorders, particularly through mechanisms associated with immune evasion and altered NKG2D signaling. In addition, genetic polymorphisms and structural variations within regulatory regions, especially within the 3'UTR, can alter miRNA binding affinity by creating, disrupting, or modifying target sites. This mini review discusses the current understanding of miRNA-mediated regulation of MICA, emphasizing the impact of allelic diversity and regulatory polymorphisms on post-transcriptional control. Furthermore, it highlights current knowledge gaps and future perspectives regarding allele-specific regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.